A liquid chromatographic method for the determination of methylene blue and leucomethylene blue in male and female Fischer 344 rat urine and male and female B6C3F1 mouse urine was developed for use in supporting toxicokinetic studies, validated, and used to analyze urine samples for a preliminary dose level range-finding study. The method was validated for a concentration range of 10.0 to 20,000 ng/mt in urine. Samples up to 75,000 ng/mL demonstrated good recoveries when diluted into the range of the calibration curve. Six sets of calibration standards were prepared in F344 male rat urine for analysis to demonstrate reproducibility and ruggedness. The stability of sample extracts was determined under various storage conditions. During the course of analyses of the animal samples, a possible metabolic process was observed. Although Azure B is a significant impurity in methylene blue trihydrate, the amount of Azure B seen in urine samples collected from rodents dosed with methylene blue trihydrate is significantly greater than the amount seen in rodent urine spiked directly with methylene blue. This observation suggests possible N-demethylation of the methylene blue as a metabolic transformation to Azure B.
Introduction
Methylene blue has long been used as an antiseptic and therapeutic agent with both human and veterinary applications. Published studies of metabolism and elimination in living organisms date back to the 1880s (1) . Over this period, numerous observations of possible negative effects of methylene blue used in therapy have been made (2) (3) (4) (5) (6) (7) (8) (9) . Although studies of methylene blue in urine have been done in the past, most have used a spectrometric method for the analyses (10) (11) (12) (13) . Additionally, most of these methods use an extraction method to remove the excreted methylene blue, but not the leuco form of methylene blue, from urine. The sample then goes through a reduction step to convert the leucomethylene blue remaining in the urine to methylene blue ( Figure 1 ) and a second extraction of the converted leucomethylene blue. Each extract is then quantified as methylene blue by spectrometry at 660 nm. Although this allows quantitation of the methylene blue and leucomethylene blue, it does not distinguish the methylene blue from its three most common N-demethylated counterparts Azure A, Azure B (Figure 2) , and Azure C, each of which absorbs strongly at 660 nm. IfN-demethylation produces one or more of these metabolites when methylene blue is metabolized, a chromatographic method is needed to quantify the metabolites. This method was developed to support long-term toxicology studies in mice and rats, monitoring methylene blue, leucomethylene blue, and demethylated forms of these molecules.
Materials and Methods

Materials
Reagents were analytical grade or higher. The following chemicals were obtained: trifluoroacetic acid, triethylamine (Sigma-Aldrich, Milwaukee, WI); acetonitrile (Fischer Scientific, Fair Lawn, NJ); sodium chloride, 1,2-dichloroethane (EM Science); deionized water Millipore Alpha-Q water purification system). The Zorbax Stable Bond C18 (150 mm • 4.6-mm i.d., 3.5-1Jm particle size) column and Zorbax Stable Bond-C18 guard columns were purchased from MAC-MOD Analytical (Chadds Ford, PA). Analytical labware consisted of either polypropylene or polyethylene (VWR Scientific Products, Atalanta, GA).
Sample extraction/concentration
Burrell model 75 wrist-action shaker (VWR Scientific Products, Atlanta, GA) was used for the liquid-liquid extraction phase. A SpeedVac model SC210A-120 sample concentrator used in conjunction with a model RVT400 refrigerated vapor trap and a model VLP120 vacuum pump were purchased from Savant Instruments (Holbrook, NY).
Standards and controls
Materials for the preparation of standards, methylene blue trihydrate, Azure B, and Basic Blue 3 were obtained from SigmaAldrich (Milwaukee, WI). Initial chromatography on the bulk material revealed a large impurity which accounted for approximately 15% of the total integrated area. Liquid chromatography-mass spectrometry (LC-MS) suggested the impurity was Azure B, one of the N-demethylated homologues of methylene blue. When needed, approximately 80 mL of urine from 7 undosed male F344 rats was pooled for use in matrix standards, quality control samples, and analysis period samples. Approximately 11.4 mL was used from the urine collected from each animal. The pooled samples were divided among four scintillation vials and stored at -20~ until used. Pooled male rat urine was used for calibration curves. A similar pool of urine was created using 7 female F344 rats for purposes of cross-validation. Two pools were also created for cross-validation from each of 7 male and 7 female B6C3FI mice by combining approximately 1-mL aliquots of urine. Adhesion of analyte and internal standard to glassware was avoided through the use of either polypropylene or polyethylene labware. Stock solutions at a concentration of 100,000 ng/mL as methylene blue were prepared from the trihydrate in deionized water. Intermediate concentration solutions were prepared at 7 levels ranging from 5.0 to 10,000 ng/mL. These solutions were used to prepare standards, quality control samples, and extract storage stability samples in rat or mouse urine at concentrations ranging from 10.0 to 20,000 ng/mL. Internal standard solutions were prepared from Basic Blue 3 at approximately 1500 ng/mL in deionized water. All standards, quality control samples, and extract storage stability samples were prepared using 0.5 mL of urine.
Subject animals
All animals were purchased from Charles River Laboratories (Raleigh, NC). A preliminary range-finding study was done using five subject Fischer 344 rats to determine whether the validated calibration range would be appropriate for processing animals from the dose levels proposed for long range definitive studies. One male animal was dosed intravenously at 2.5 mg/kg. One male and one female were gavaged at 2.5 mg/kg and one male and one female were gavaged at 50 mg/kg. The dose formulations were prepared by dissolving methylene blue trihydrate in water. The animals were placed in metabolism cages affording separate collection of urine and feces while maintaining the collection flasks at dry ice temperatures between collection time points. Samples were removed from the cages and weighed at 6, 12, 24, and 48 h. Blank urine was collected from undosed animals in a similar fashion.
Processing of specimen batches
Extraction specimens were processed in batches consisting of six calibration standards (10.0 to 20,000 ng/mL), QC samples, extract storage stability samples, and control (blank) samples. Following processing, each standard was split into two aliquots, one of which was run at the beginning and the other at the end of each analytical run. A total of 48 samples/standards were processed in each run. Analysis preparation for each animal sample consisted of two separate extractions, one extraction for the quantitation of excreted methylene blue, and the second extraction for the quantitation of leucomethylene blue. In order to prepare samples for extraction of methylene blue, 200 lJL of 1M NaCl solution and 100 IJL of Basic Blue 3 internal standard solution were added to 0.5 mL of urine in polypropylene tubes. Tube contents were vortex mixed gently. A 4-mL aliquot of 1,2-dichloroethane was added to each tube, and the contents were shaken for 15 min and then centrifuged for 5 min with a table-top centrifuge. The 1,2-dichloroethane layer was transferred to a clean 4-mL polypropylene vial using a polyethylene pipette and evaporated to dryness with a Savant Speedvac sample concentrator set to medium heat. A 200-~L aliquot of 0.1% trifluoroacetic acid solution and 100 ~L of acetonitrile were added to each vial, and the contents were sonicated for 6 min and transferred to a polypropylene autosampler vial insert. A second extraction was then performed to remove the leucomethylene blue from the samples following conversion of the leucomethylene blue present to methylene blue. To convert the leucomethylene blue to methylene blue, 1001JL of 1N HC1 was added to the tubes. The tubes were immersed in boiling water for 20 min and allowed to cool to room temperature. The methylene blue which formed from oxidation of leucomethylene blue was then extracted and prepared for analysis using the same technique used for the original sample extraction. components were then flushed from the system by ramping to 80:20 in 2 rain, maintaining 80:20 for 3 rain, and returning to 33:67.
Analysis
pH adjusted to ~2.74 with triethylamine. Flow of the mobile phase was set at 1.0 mL/min. Injection volume was 50 IJL.
Results and Discussion
tinearity and reproducibility
Linearity was established by preparation and analysis of six separate sets of standards. Each set consisted of 10.0, 20.0, 200, 1000, 10,000, and 20,000 ng/mL concentrations. Calibration curves were generated with a weighted linear least-squares fit, using the inverse of the concentration as the weighting factor (Figure 3) . Following this weighting scheme, correlation coefficients reflecting the fit of the regression line to calibration data obtained for spiked urine standards and solvent standards exceeded 0.99. Another measure of linearity was obtained through examination of relative errors in calculated concentrations. Interassay and equivalent calibration curve data obtained from urine calibration standards demonstrated acceptable reproducibility of the slopes and correlation coefficients. Over the course of the analytical runs, the mean and standard deviation (+_ SD) of the y-intercepts were calculated. The y-intercepts derived from the calibration curves were within • 2.8 SD of zero, providing additional evidence that the method is selective. Results of the linear regressions of the six calibration curves are summarized in Table I .
To demonstrate that samples with concentrations higher than the highest calibration standard could be diluted into the range of the calibration curve, two samples were prepared at 75,000 ng/mL and diluted. The samples showed recoveries of 97.0 and 98.0% when diluted into the range of a calibration curve. The method was cross-validated using pooled male and female B6C3F1 mouse urine and female F344 rat urine.
Relative Error (%) +14 +12 + 5.0 -1.5 -3.5 -2.0 -11.4 -11.9 -1.7 -1.7 + 2.0 + 2.0
Recovery/limit of detection (LOD)/limit of quantitation (LOQ)
Assay results for a single set of matrix standards and solvent standards are presented in Table II .
The average recovery of matrix verses solvent standards was 118 over a concentration range from 10.0 to 20,000 ng/mL. A combination of three quality control samples and three low standards at a nominal concentration of 10.0 ng/mL showed an average measured concentration of 9.45 ng/mL (94.5% of nominal) with an SD of 1.30 ng/mL (14% RSD). The LOD, defined as three times the SD, was determined to be 3.9 ng/mL. The LOQ, defined as 10 times the SD, was determined to be 13.0 ng/mL. When determining the concentration to be used for the lowest standard, 6 replicates were prepared at decreasing concentrations until the SD among the replicates was approximately 30%. The large SD, which was accepted to give the lowest possible concentrations, caused the LOQ to be slightly greater than the lowest standard.
Precision and accuracy
Intra-and interassay precision were determined at 20, 1000, and 20,000 ng/mL. Triplicate preparations and determinations at each concentration were made on six distinct batches. Precision was calculated as the pooled RSD within batches and across batches. The results are summarized in Table III .
Storage stability
The storage stability samples were prepared in both pooled rat and pooled mouse urine in polypropylene centrifuge tubes to produce samples for storage at a concentration of 10,000 ng/mL. The samples were stored in a freezer at-20~ in the dark. Samples were removed periodically over 45 days of storage. Effects of thawing and refreezing samples were also investigated. Triplicate stability study samples were prepared at 20.0, 1000, and 20,000 ng/mL concentrations for storage at -20~ for 9 days prior to processing and analysis. These samples were thawed and refrozen three times prior to processing and analysis. significantly more methylene blue and leucomethylene blue excreted by female rats than by male rats after oral dosing. The table lists the concentration of methylene blue and leucomethylene blue in each urine sample and the total mass of methylene blue and leucomethylene blue excreted based on the measured density of the urine and the total amount of urine collected (Figure 4 ).
Conclusions
Methylene blue and ]eucomethylene blue in male and female rat and mouse urine can be quantitated over the range of 10 to 20,000 ng/mL. The method was successfully applied to samples from a preliminary dose range-finding study. Both methylene blue and leucomethylene blue were quantified in animals dosed intravenously and orally. The method could also be expanded to include quantitation of Azure B. The method provides differentiation of methylene blue and other similar blue dyes which earlier spectrometric methods did not provide. The stability of methylene blue in urine extracts prepared for analysis and stored under ambient and refrigerator conditions was determined by analyzing analysis period samples prepared at 10.0, 1000, and 20,000 ng/mL. Methylene blue extracts at various concentrations can be stored at ambient temperature for three days after extraction and preparation for analysis. Extracts may be stored at refrigerator temperatures for nine days. Methylene blue in urine may be stored under freezer conditions and subjected to freeze-thaw cycles without adversely affecting quantitation results. Urine samples containing methylene blue at a concentration of 10,000 ng/mL were stable when stored under freezer conditions (-20~ for up to 45 days. Continued LC-MS work on other peaks seen in samples collected from dosed animals will determine if other demethylated components are present. Further study is warranted to determine whether differences in Azure B levels are the result of metabolism or bioavailability factors.
